Evidence map›Paper›PMID 41800263›Full record

ArticleInternational journal of biological sciences2026

ANXA1-mediated mTOR/FABP4 Inhibition Drives Antifibrotic Macrophage Reprogramming in Lupus Nephritis.

Juan Tao, Qingyu Cheng, Pinjie Zhang, Guizhen Yu, Qi Chen, Manwen Yang, Qiqin Wu, Haopeng Fang, Haibo Wu, Xiaoyuan Song and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Juan TaoDepartment of Rheumatology and Immunology, The First Affiliated Hospital of the USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Qingyu ChengInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230071, China.
Pinjie ZhangEmergency Department, Peking University Shenzhen Hospital, Shenzhen 518000, China.
Guizhen YuKidney Disease Center, the First Affiliated Hospital, College of Medicine, Zhejiang University; Key Laboratory of Kidney Disease Prevention and Control Technology, Zhejiang Province; Institute of Nephrology, Zhejiang University; Zhejiang Clinical Research Center of Kidney and Urinary System Disease, Hangzhou 310003, China.
Qi ChenDepartment of Dermatology, The First Affiliated Hospital of the USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Manwen YangDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Qiqin WuDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Haopeng FangDivision of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.
Haibo WuDepartment of Pathology, The First Affiliated Hospital of the USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Xiaoyuan SongMOE Key Laboratory for Membraneless Organelles and Cellular Dynamics, Hefei National Laboratory for Physical Sciences at the Microscale, CAS Key Laboratory of Brain Function and Disease, School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China.
Zhu ChenDepartment of Rheumatology and Immunology, The First Affiliated Hospital of the USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China.
Min ChenRenal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University; Key Laboratory of Renal Disease, Ministry of Health of China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment (Peking University), Ministry of Education, Beijing 100034, China.
Xiaoming MengInflammation and Immune Mediated Diseases Laboratory of Anhui Province, the Key Laboratory of Anti-inflammatory of Immune Medicines, Ministry of Education, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei 230032, China.
Mingxing LeiKey Laboratory of Biorheological Science and Technology of Ministry of Education and 111 Project Laboratory of Biomechanics and Tissue Repair, College of Bioengineering, Chongqing University, Chongqing 400044, China.
Tengchuan JinInstitute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei 230071, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammation and fibrosis are central pathological processes in lupus nephritis (LN). Annexin A1 (ANXA1), a protein highly expressed in myeloid cells, is a key modulator of inflammation and fibrosis. In this study, we found that renal ANXA1 expression was elevated in LN patients and correlated positively with the severity of fibrosis. Single-cell RNA sequencing identified a distinct monocyte-derived

Indexed as

Annexin A1Fatty Acid-Binding ProteinsLupus NephritisMacrophagesTOR Serine-Threonine KinasesAnimalsFemaleFibrosisHumansKidneyMicePeptidesReceptors, Formyl PeptideReceptors, LipoxinAnnexin A1annexin A1 peptide (2-26)ANXA1 protein, humanFatty Acid-Binding ProteinsFPR2 protein, humanPeptidesReceptors, Formyl PeptideReceptors, LipoxinTOR Serine-Threonine Kinasesannexin A1lipid metabolic reprogramminglupus nephritismacrophagerenal fibrosis

Identifiers

PMID41800263
PMCPMC12965141

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.